Trial Profile
A Phase 1 Study of CNTO 328 (Siltuximab) in Combination With Bortezomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 10 Dec 2012 Planned End Date changed from 1 Nov 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 20 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 23 Feb 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.